ScripsAmerica, Inc. (OTCMKTS:SCRC) Gets Active on Marketing Promises
ScripsAmerica, Inc. (OTCMKTS:SCRC) is 50% away from its January levels, which were boosted by a promotion at the end of 2012. Still, Monday’s buying volumes are the second highest in the company’s history, inviting speculation of factors that may make SCRC move out of the valley. On Monday, the ticker reached 17 cents after adding more than 13%. Nearly 800 thousand shares were bought. 
What is easy to see are the company’s more frequent press releases, promising an efficient distribution of its drugs. The mention of financial results also honed the interest. SCRC boasts it will produce a widespread drug, possibly as sought-after as children’s Tylenol. To do this, SCRC has the following resources: 
- $3,309 cash
- $2 million total current assets
- $1.9 million total current liabilities
- $150,050 revenues
- $740,992 net loss
These data show a pharmaceutical company that manages quite well to stay afloat. Still, the stability was broken by promoters, when they inflated the stock price to unsustainable levels. Currently, SCRC is priced around $10.5 million, with a little more than 61 million shares outstanding, a very low count for penny stock companies.
On the plus side, recently SCRC signed a manufacturing agreement for production of the RapiMed pain reliever and anti-temperature drug. The partner for this drug will be CapriPharma, Inc. The product launch of the quick relief pills is planned for September. This is some indication that SCRC has a real product to show and not just preliminary developments of very advanced drugs that may take years to see market. SCRC already delivers drugs across the US, and although its revenues are still modest, the company has an outlook to continue operations.
The latest promoter for SCRC is Stock Guru, receiving $11,600 for the December pumps. Stock Guru has a long list of previous promotions, one of the noisiest being Great American Energy, Inc. (OTCBB:SRBL), a stock continuously taken on by promoters when they deem it low enough. Since the April promotion by Stock Guru, SRBL retreaded by about 60% before starting to move out of the valley again.
Time will show if SCRC keeps up the good pace or it gets a breather and slides back from the steep climb. Still, if you decide that the price is right, be prepared to absorb the losses as well.
